Bionano Genomics, Inc.
BNGO
$4.08
-$0.02-0.49%
| Weiss Ratings | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.97 | |||
| Price History | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -12.82% | |||
| 30-Day Total Return | -48.60% | |||
| 60-Day Total Return | -70.90% | |||
| 90-Day Total Return | -77.00% | |||
| Year to Date Total Return | -73.36% | |||
| 1-Year Total Return | -94.09% | |||
| 2-Year Total Return | -99.48% | |||
| 3-Year Total Return | -99.62% | |||
| 5-Year Total Return | -99.20% | |||
| 52-Week High % Change | -94.58% | |||
| 52-Week Low % Change | 9.83% | |||
| Price | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $75.60 | |||
| 52-Week Low Price | $3.73 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Mar 08, 2024 | |||
| Valuation | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.97M | |||
| Enterprise Value | 17.47M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -147.49 | |||
| Earnings Per Share Growth | -64.80% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.18 | |||
| Price/Book (Q) | 0.12 | |||
| Enterprise Value/Revenue (TTM) | 0.52 | |||
| Price | $4.08 | |||
| Enterprise Value/EBITDA (TTM) | -0.22 | |||
| Enterprise Value/EBIT | -0.19 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.43M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 858 888 7600 | |||
| Address | 9540 Towne Centre Drive San Diego, CA 92121 | |||
| Website | www.bionano.com | |||
| Country | United States | |||
| Year Founded | 2003 | |||
| Profitability | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -282.16% | |||
| Profit Margin | -407.34% | |||
| Management Effectiveness | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -43.66% | |||
| Return on Equity | -- | |||
| Income Statement | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 33.33M | |||
| Total Revenue (TTM) | 33.33M | |||
| Revenue Per Share | $23.29 | |||
| Gross Profit (TTM) | -599.00K | |||
| EBITDA (TTM) | -78.84M | |||
| EBIT (TTM) | -94.06M | |||
| Net Income (TTM) | -135.78M | |||
| Net Income Avl. to Common (TTM) | -135.78M | |||
| Total Revenue Growth (Q YOY) | -34.83% | |||
| Earnings Growth (Q YOY) | 60.69% | |||
| EPS Diluted (TTM) | -147.49 | |||
| EPS Diluted Growth (Q YOY) | 83.98% | |||
| Balance Sheet | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 11.95M | |||
| Cash Per Share (Q) | $8.35 | |||
| Total Current Assets (Q) | 46.98M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 48.87M | |||
| Current Ratio (Q) | 1.426 | |||
| Book Value Per Share (Q) | $33.14 | |||
| Total Assets (Q) | 87.36M | |||
| Total Current Liabilities (Q) | 32.95M | |||
| Total Debt (Q) | 22.45M | |||
| Total Liabilities (Q) | 38.49M | |||
| Total Common Equity (Q) | 48.87M | |||
| Cash Flow | BNGO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 15.47M | |||
| Cash from Financing (TTM) | 50.91M | |||
| Net Change in Cash (TTM) | -25.77M | |||
| Levered Free Cash Flow (TTM) | -53.19M | |||
| Cash from Operations (TTM) | -92.20M | |||
